Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 1, 2026Open Access

Development of HPMC-Based Matrix Tablets for the Sustained Release of Metformin Hydrochloride

View Full Paper
Ask AI
Bookmark
Share

Authors

*R*Akshay Kumar Sinha1, Prof. Dr. Pankaj Kumar Sharma2, Prof. Dr. Jaya Sharma3, Prof. Ms. Priyanka Singh Rajora4

Discussion

Loading...

Member takes

Overview

Randomized trial evaluates sustained-release formulation of Metformin in diabetes, suggesting effective alternatives for dosing.

Key Points

  • This investigation aims to develop and evaluate sustained-release matrix tablets for Metformin Hydrochloride using various polymers.
  • Created 27 formulations using a 3.2 full factorial design through direct compression and wet granulation.
  • Conducted pre-formulation studies including FTIR and DSC, and post-compression parameters as per IP 2022/ USP 46.
  • Compared dissolution profiles of optimized formulations with the marketed Glycomet SR 500 mg using similarity factor (f2).
  • Optimized formulation F5 (22.5% Xanthan Gum + 17.5% Guar Gum) released 87.6% of the drug over 12 hours with f2 = 58.4, meeting pharmacopoeial acceptance.
  • Synthetic polymer formulation S5 (HPMC K100M 22.5%/K15M 17.5%) showed similar performance with f2 = 61.4.
  • All formulations met official limits for hardness (7.4 – 8.8 kp), friability (0.22 – 0.68%), weight variation (<3%), and drug content (98.4 – 101.8%).

Cite This Study

*Akshay Kumar Sinha1, Prof. Dr. Pankaj Kumar Sharma2, Prof. Dr. Jaya Sharma3, Prof. Ms. Priyanka Singh Rajora4 (2026) studied this question.

synapsesocial.com/papers/6a6d98b4e258b358b3c6c7d3https://doi.org/10.5281/zenodo.21702058
View Full Paper
Ask AI
Bookmark
Share